Guangzhou Kafen Biotech Co.,Ltd
|Place of Origin:||Guangdong|
|Certification:||USP, GMP ,ISO9001, UKAS,BP|
|Minimum Order Quantity:||10g|
|Packaging Details:||Disguised and discreet or according to every customer's requirements|
|Delivery Time:||within 8 hours after receiving your payment|
|Payment Terms:||D/A, L/C, D/P, T/T, Western Union, MoneyGram, Bitcoin|
|Storage:||Keep In Dry And Avoid Light, Heat And Moisture||Suitable For:||Adult Or Bodybuilders|
|Assay:||99%||Package:||Disguised And Discreet Or According To Every Customer's Requirements|
Rimonabant / Acomplia Muscle Gain Steroids To Increase Muscle Weight And Size
1. Quick Details:
Product Name: Rimonabant
Chemical Name: Acomplia
Molecular Formula: C22H21Cl3N4O
Payment Terms:TT, Western Union, Money Gram,Bitcoin
2 . Description:
Rimonabant is the generic name for Acomplia, which is an appetite suppressant and smoking cessation product manufactured by the French pharmaceutical company Sanofi-Aventis.Rimonabant is a cannabinoid (CB1) receptor antagonist, which means it blocks CB1 receptors in the brain and peripheral organs, which is said to suppress appetite and possibly reduce tobacco dependence.
Rimonabant (Acomplia) acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle2.Rimonabant (Acomplia) switches off the same brain circuits that make people hungry when they smoke cannabis.
CB1 receptor blockade with Rimonabant acts to decrease the overactivity of the endocannabinoid system (EC system).3,4 The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism.
3 . Function:
Rimonabant (Acomplia) was studied to be used complementary to diet and exercise to treat obese or overweight patients who suffer from type 2 diabetes and abnormal levels of fat in the blood.Sanofi argued that Acomplia could also prevent the risk of cardiovascular disease.Patients with large waist circumference (102 cm in men and 88 cm in women) were said to most benefit from taking the drug.
Rimonabant (Acomplia) (Zimulti in the US) was studied by Sanofi-Aventis as an aid to smoking cessation based on studies for up to one year in over 6,500 smokers motivated to quit smoking.
Sanofi-Aventis submitted a New Drug Application to the FDA, which in turn issued a non-approvable letter for Zimulti for use in smoking cessation. In June of 2007, the FDA's Endocrine and Metabolic Drugs Advisory Committee recommended against the approval of rimonabant due to concerns over serious side effects such as suicidality.
4 . Specification:
|Test Items||Specification||Test Results|
|Appearance||white crystalline powder||white crystalline powder|
|Solubility||soluble in methanol||conforms|
|T.L.C.||Only one spot||Only one spot|
|Conclusion: The specification conforms Enterprise Standard.|